Please assess the completion status of the following clinical trial:

Trial Title: Escalating Ketamine Doses and Pre-emption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Consecutive patients, who were scheduled to undergo general or orthopedic oncologic surgery under general anesthesia~Exclusion Criteria:~1. allergy to opioids, ketamine or non-steroidal anti-inflammatory drugs (NSAIDs)~2. history of lasting chronic pain or psychiatric disorders or had used opioids or psychotropic drugs of any sort during the past two weeks~3. soldiers and pregnant women

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Set 1 (Type: ACTIVE_COMPARATOR): group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
- set 2 (Type: ACTIVE_COMPARATOR): 2nd set received ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
- set 3 (Type: ACTIVE_COMPARATOR): 3rd set one group had ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS

Based on this trial design, predict the completion outcome and termination type (if applicable).